Abstract
Oxyntomodulin and peptide tyrosine–tyrosine (PYY) are released from intestinal enteroendocrine cells in response to a meal. These circulating hormones are considered to be satiety signals, as they have been found to decrease food intake, body weight and adiposity in rodents. Their effect on energy homeostasis is mediated by the hypothalamus and brainstem, and several studies have demonstrated alterations in neuropeptide signaling within the arcuate nucleus. The weight loss that has been observed in animal models after repeated administration of oxyntomodulin and PYY has led to interest in developing these peptides as antiobesity therapies in humans. Indeed, preliminary studies have found that oxyntomodulin or PYY administration reduces food intake and body weight effectively in overweight human volunteers. This research suggests that modulation of these gut hormones could prove to be effective long-term therapies in the quest to combat the obesity epidemic.
Key Points
-
Oxyntomodulin and peptide tyrosine–tyrosine (PYY) are gut peptides that are released postprandially
-
Oxyntomodulin and PYY act as satiety signals via effects on appetite centers such as the hypothalamus and brainstem
-
Exogenous administration of oxyntomodulin or PYY3–36 reduces energy intake, adiposity and body weight in animals
-
Several studies suggest that drug therapy based on these hormones could be an effective treatment for human obesity
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
Purchase on Springer Link
Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Stanley S et al. (2005) Hormonal regulation of food intake. Physiol Rev 85: 1131–1158
Tatemoto K and Mutt V (1980) Isolation of two novel candidate hormones using a chemical method for finding naturally occurring polypeptides. Nature 285: 417–418
Bataille D et al. (1981) Bioactive enteroglucagon (oxyntomodulin): present knowledge on its chemical structure and its biological activities. Peptides 2 (Suppl 2): 41–44
Batterham RL et al. (2003) Inhibition of food intake in obese subjects by peptide YY3–36 . N Engl J Med 349: 941–948
Wynne K et al. (2005) Subcutaneous oxyntomodulin reduces body weight in overweight and obese subjects: a double-blind, randomized, controlled trial. Diabetes 54: 2390–2395
Strader AD and Woods SC (2005) Gastrointestinal hormones and food intake. Gastroenterology 128: 175–191
Taylor RG et al. (1992) Expression of ileal glucagon and peptide tyrosine–tyrosine genes. Response to inhibition of polyamine synthesis in the presence of massive small-bowel resection. Biochem J 286: 737–741
Anini Y et al. (1999) Comparison of the postprandial release of peptide YY and proglucagon-derived peptides in the rat. Pflugers Arch 438: 299–306
Schjoldager BT et al. (1988) Oxyntomodulin: a potential hormone from the distal gut. Pharmacokinetics and effects on gastric acid and insulin secretion in man. Eur J Clin Invest 18: 499–503
Adrian TE et al. (1985) Effect of peptide YY on gastric, pancreatic, and biliary function in humans. Gastroenterology 89: 494–499
Allen JM et al. (1984) Effects of peptide YY and neuropeptide Y on gastric emptying in man. Digestion 30: 255–262
Hoentjen F et al. (2001) Effect of circulating peptide YY on gallbladder emptying in humans. Scand J Gastroenterol 36: 1086–1091
Tang-Christensen M et al. (2001) Glucagon-like peptide containing pathways in the regulation of feeding behaviour. Int J Obes Relat Metab Disord 25 (Suppl 5): S42–S47
Holst JJ (1999) Glucagon-like peptide 1 (GLP-1): an intestinal hormone, signaling nutritional abundance, with an unusual therapeutic potential. Trends Endocrinol Metab 10: 229–235
Baldissera FG and Holst JJ (1984) Glucagon-related peptides in the human gastrointestinal mucosa. Diabetologia 26: 223–228
Kervran A et al. (1987) Distribution of oxyntomodulin and glucagon in the gastrointestinal tract and the plasma of the rat. Endocrinology 121: 704–713
Ghatei MA et al. (1983) Molecular forms of human enteroglucagon in tissue and plasma: plasma responses to nutrient stimuli in health and in disorders of the upper gastrointestinal tract. J Clin Endocrinol Metab 57: 488–495
Le Quellec A et al. (1992) Oxyntomodulin-like immunoreactivity: diurnal profile of a new potential enterogastrone. J Clin Endocrinol Metab 74: 1405–1409
Glover I et al. (1983) Conformational flexibility in a small globular hormone: X-ray analysis of avian pancreatic polypeptide at 0.98-Å resolution. Biopolymers 22: 293–304
Conlon JM (2002) The origin and evolution of peptide YY (PYY) and pancreatic polypeptide (PP). Peptides 23: 269–278
Tatemoto K et al. (1982) Neuropeptide Y—a novel brain peptide with structural similarities to peptide YY and pancreatic polypeptide. Nature 296: 659–660
Adrian TE et al. (1985) Human distribution and release of a putative new gut hormone, peptide YY. Gastroenterology 89: 1070–1077
Ekblad E and Sundler F (2002) Distribution of pancreatic polypeptide and peptide YY. Peptides 23: 251–261
Lin HC and Chey WY (2003) Cholecystokinin and peptide YY are released by fat in either proximal or distal small intestine in dogs. Regul Pept 114: 131–135
Feinle-Bisset C et al. (2005) Fat digestion is required for suppression of ghrelin and stimulation of peptide YY and pancreatic polypeptide secretion by intraduodenal lipid. Am J Physiol Endocrinol Metab 289: E948–E953
Fu-Cheng X et al. (1997) Mechanisms of peptide YY release induced by an intraduodenal meal in rats: neural regulation by proximal gut. Pflugers Arch 433: 571–579
Grandt D et al. (1994) Two molecular forms of peptide YY (PYY) are abundant in human blood: characterization of a radioimmunoassay recognizing PYY1–36 and PYY3–36 . Regul Pept 51: 151–159
Mentlein R et al. (1993) Proteolytic processing of neuropeptide Y and peptide YY by dipeptidyl peptidase IV. Regul Pept 49: 133–144
Boonacker E and Van Noorden CJ (2003) The multifunctional or moonlighting protein CD26/DPPIV. Eur J Cell Biol 82: 53–73
Zhu L et al. (2003) The role of dipeptidyl peptidase IV in the cleavage of glucagon family peptides: in vivo metabolism of pituitary adenylate cyclase activating polypeptide-(1–38). J Biol Chem 278: 22418–22423
Dakin CL et al. (2001) Oxyntomodulin inhibits food intake in the rat. Endocrinology 142: 4244–4250
Dakin CL et al. (2004) Peripheral oxyntomodulin reduces food intake and body weight gain in rats. Endocrinology 145: 2687–2695
Dakin CL et al. (2002) Repeated ICV administration of oxyntomodulin causes a greater reduction in body weight gain than in pair-fed rats. Am J Physiol Endocrinol Metab 283: E1173–E1177
Challis BG et al. (2003) Acute effects of PYY3–36 on food intake and hypothalamic neuropeptide expression in the mouse. Biochem Biophys Res Commun 311: 915–919
Halatchev IG et al. (2004) Peptide YY3–36 inhibits food intake in mice through a melanocortin-4 receptor-independent mechanism. Endocrinology 145: 2585–2590
Martin NM et al. (2004) Pre-obese and obese agouti mice are sensitive to the anorectic effects of peptide YY3–36 but resistant to ghrelin. Int J Obes Relat Metab Disord 28: 886–893
Chelikani PK et al. (2005) Intravenous infusion of PYY3–36 potently inhibits food intake in rats. Endocrinology 146: 879–888
Pittner RA et al. (2004) Effects of PYY3–36 in rodent models of diabetes and obesity. Int J Obes Relat Metab Disord 28: 963–971
Riediger T et al. (2004) Peptide YY directly inhibits ghrelin-activated neurons of the arcuate nucleus and reverses fasting-induced c-Fos expression. Neuroendocrinology 79: 317–326
Talsania T et al. (2005) Peripheral exendin-4 and peptide YY3–36 synergistically reduce food intake through different mechanisms in mice. Endocrinology 146: 3748–3756
Batterham RL et al. (2002) Gut hormone PYY3–36 physiologically inhibits food intake. Nature 418: 650–654
Sileno AP et al. (2006) Lower mean weight after 14 days intravenous administration peptide YY3–36 (PYY3–36) in rabbits. Int J Obes (Lond) 30: 68–72
Koegler FH et al. (2005) Peptide YY3–36 inhibits morning, but not evening, food intake and decreases body weight in rhesus macaques. Diabetes 54: 3198–3204
Boggiano MM et al. (2005) PYY3–36 as an anti-obesity drug target. Obes Rev 6: 307–322
Tschop M et al. (2004) Physiology: does gut hormone PYY3–36 decrease food intake in rodents? Nature 430: 165–167
Challis BG et al. (2004) Mice lacking pro-opiomelanocortin are sensitive to high-fat feeding but respond normally to the acute anorectic effects of peptide-YY3–36 . Proc Natl Acad Sci USA 101: 4695–4700
Moran TH et al. (2004) Peptide YY3–36 inhibits gastric emptying and produces acute reductions in food intake in rhesus monkeys. Am J Physiol Regul Integr Comp Physiol 288: R384–R388
Abbott CR et al. (2005) The importance of acclimatisation and habituation to experimental conditions when investigating the anorectic effects of gastrointestinal hormones in the rat. Int J Obes (Lond) 30: 288–292
Broadwell RD and Brightman MW (1976) Entry of peroxidase into neurons of the central and peripheral nervous systems from extracerebral and cerebral blood. J Comp Neurol 166: 257–283
Cone RD et al. (2001) The arcuate nucleus as a conduit for diverse signals relevant to energy homeostasis. Int J Obes Relat Metab Disord 25 (Suppl 5): S63–S67
Horvath TL (2005) The hardship of obesity: a soft-wired hypothalamus. Nat Neurosci 8: 561–565
Schwartz MW et al. (2000) Central nervous system control of food intake. Nature 404: 661–671
Baggio LL et al. (2004) Oxyntomodulin and glucagon-like peptide-1 differentially regulate murine food intake and energy expenditure. Gastroenterology 127: 546–558
Turton MD et al. (1996) A role for glucagon-like peptide-1 in the central regulation of feeding. Nature 379: 69–72
Fehmann HC et al. (1994) Stable expression of the rat GLP-I receptor in CHO cells: activation and binding characteristics utilizing GLP-I7–36-amide, oxyntomodulin, exendin-4, and exendin9–39 . Peptides 15: 453–456
Leibowitz SF and Alexander JT (1991) Analysis of neuropeptide Y-induced feeding: dissociation of Y1 and Y2 receptor effects on natural meal patterns. Peptides 12: 1251–1260
Naveilhan P et al. (1999) Normal feeding behavior, body weight and leptin response require the neuropeptide Y Y2 receptor. Nat Med 5: 1188–1193
Abbott CR et al. (2005) Blockade of the neuropeptide Y Y2 receptor with the specific antagonist BIIE0246 attenuates the effect of endogenous and exogenous peptide YY3–36 on food intake. Brain Res 1043: 139–144
Broberger C et al. (1997) Subtypes Y1 and Y2 of the neuropeptide Y receptor are respectively expressed in pro-opiomelanocortin- and neuropeptide-Y-containing neurons of the rat hypothalamic arcuate nucleus. Neuroendocrinology 66: 393–408
Acuna-Goycolea C and van den Pol AN (2005) Peptide YY3–36 inhibits both anorexigenic proopiomelanocortin and orexigenic neuropeptide Y neurons: implications for hypothalamic regulation of energy homeostasis. J Neurosci 25: 10510–10519
Conrad CD and McEwen BS (2000) Acute stress increases neuropeptide Y mRNA within the arcuate nucleus and hilus of the dentate gyrus. Brain Res Mol Brain Res 79: 102–109
Makino S et al. (2000) Differential regulation of neuropeptide Y mRNA expression in the arcuate nucleus and locus coeruleus by stress and antidepressants. J Neuroendocrinol 12: 387–395
Koda S et al. (2005) The role of the vagal nerve in peripheral PYY3–36-induced feeding reduction in rats. Endocrinology 146: 2369–2375
Cohen MA et al. (2003) Oxyntomodulin suppresses appetite and reduces food intake in humans. J Clin Endocrinol Metab 88: 4696–4701
Wynne K et al. Oxyntomodulin increases energy expenditure in addition to decreasing energy intake in overweight and obese humans: a randomized controlled trial. Int J Obes [doi: 10.1038/sj.ijo.0803344]
Degen L et al. (2005) Effect of peptide YY3–36 on food intake in humans. Gastroenterology 129: 1430–1436
Nastech Pharmaceutical Company Inc. (online 29 June 2004) Nastech News: Nastech announces positive phase 1-C clinical results of PYY3–36 nasal spray for obesity [http://investor.nastech.com/phoenix.zhtml?c=83674&p=irol-newsArticle&ID=586170&highlight=] (accessed 1 September 2006)
Besterman HS et al. (1979) Gut hormones in tropical malabsorption. BMJ 2: 1252–1255
Holst JJ et al. (1979) Plasma enteroglucagon after jejunoileal bypass with 3:1 or 1:3 jejunoileal ratio. Scand J Gastroenterol 14: 205–207
Adrian TE et al. (1986) Peptide YY abnormalities in gastrointestinal diseases. Gastroenterology 90: 379–384
Naslund E et al. (1997) Gastrointestinal hormones and gastric emptying 20 years after jejunoileal bypass for massive obesity. Int J Obes Relat Metab Disord 21: 387–392
Alvarez BM et al. (2002) Peptide YY secretion in morbidly obese patients before and after vertical banded gastroplasty. Obes Surg 12: 324–327
Le Roux CW et al. (2005) The putative satiety hormone PYY is raised in cardiac cachexia associated with primary pulmonary hypertension. Heart 91: 241–242
Le Roux CW et al. (2006) Attenuated peptide YY release in obese subjects is associated with reduced satiety. Endocrinology 147: 3–8
Ahituv N et al. (2006) A PYY Q62P variant linked to human obesity. Hum Mol Genet 15: 387–391
Neary NM et al. (2005) Peptide YY3–36 and glucagon-like peptide-17–36 inhibit food intake additively. Endocrinology 146: 5120–5127
Shechter Y et al. (2005) Reversible PEGylation of peptide YY3–36 prolongs its inhibition of food intake in mice. FEBS Lett 579: 2439–2444
Holst JJ (2006) Glucagon-like peptide-1: from extract to agent. The Claude Bernard Lecture 2005. Diabetologia 49: 253–260
Acknowledgements
The work on gastrointestinal peptides within the laboratory is funded by grants from the Wellcome Trust and Medical Research Council.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
K Wynne declared she has no competing interests.
The use of oxyntomodulin for the treatment of obesity is the subject of two patent applications (WO 2003/022304 and WO 2004/06285) in the name of Imperial College Innovations, which are exclusively licensed to Thiakis Limited. SR Bloom is a Director of Thiakis Limited.
Rights and permissions
About this article
Cite this article
Wynne, K., Bloom, S. The role of oxyntomodulin and peptide tyrosine–tyrosine (PYY) in appetite control. Nat Rev Endocrinol 2, 612–620 (2006). https://doi.org/10.1038/ncpendmet0318
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/ncpendmet0318
This article is cited by
-
Role of the gut microbiota in host appetite control: bacterial growth to animal feeding behaviour
Nature Reviews Endocrinology (2017)
-
Ghrelin, the proglucagon-derived peptides and peptide YY in nutrient homeostasis
Nature Reviews Gastroenterology & Hepatology (2012)
-
Rosiglitazone decreases fasting plasma peptide YY3–36 in type 2 diabetic women: a possible role in weight gain?
Acta Diabetologica (2012)
-
Changes in neurohormonal gut peptides following bariatric surgery
International Journal of Obesity (2011)
-
Effect of weight loss by a low-fat diet and a low-carbohydrate diet on peptide YY levels
International Journal of Obesity (2010)